{"symbol":"REGN","fiscalQuarter":"Q2-2012","reportDate":"2012-07-25","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2012","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 6.09%","keyNumbers":[{"metric":"EPS","actual":"$0.90","expected":"N/A","surprise":"+234.57%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our earnings performance this quarter.","Our focus remains on advancing our pipeline and delivering value."],"summary":"Management expressed satisfaction with the earnings results, highlighting their commitment to pipeline development. They remain focused on growth opportunities."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong earnings per share of $0.90 significantly exceeded expectations, contributing to a 6.09% increase in stock price. The company did not provide revenue figures or future guidance, but management's positive tone suggests confidence in ongoing projects. Investors may view this earnings surprise as a sign of the company's strong performance in a competitive market.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2012 earnings: EPS beat expectations. Stock up 6.09%. Full breakdown."}}